AGITG Trial News

The AGITG currently has eight studies open to recruitment and ten studies in follow up. The table below details the trials that are currently accruing patients. Recruited Target ACTICCA-1- Gallbladder carcinoma 0 50 ALT-GIST- GI Stromal Tumour 29 240 ASCOLT – Colorectal cancer 186 200 CONTROL NETs – NeuroEndocrine Tumour 38 48 INTERAACT – Anal cancer … Read More

December 13, 2016

Advanced GIST Study closing

The impending closure of the Advanced GIST Study, a randomised phase III international study of imatinib in metastatic or locally advanced gastrointestinal stromal tumours (GIST), reflects a critical milestone in the management of this disease.  The AGITG was fortunate to be involved at the outset in this important study, which … Read More

December 7, 2016

Update on INTEGRATE II

INTEGRATE II, an AGITG led Phase III clinical trial in gastro-oesophageal cancer has opened to recruitment.  Support for the final INTEGRATE II trial design was received from Bayer in November 2015.  INTEGRATE II is a Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) which … Read More

December 7, 2016

4th Preceptorship in Colorectal Cancer

The 2016 AGITG Preceptorship in Colorectal Cancer was held on  Friday 11th and Saturday 12th November 2016 in Melbourne. 36 Senior trainees and Junior consultants attended a two day intensive learning course based on a complete review of literature to understand evolution of treatment for colorectal cancer in the adjuvant and metastatic … Read More

December 6, 2016

InterAACT now open at several sites

InterAACT is an international, multicentre trial aiming to establish which chemotherapy regimen is more effective for rare inoperable advanced or metastatic anal cancer. By comparing two well-known and widely used combination chemotherapies (cisplatin plus 5-fluorouracil versus carboplatin plus weekly paclitaxel), we aim to demonstrate which one is more effective and … Read More

December 6, 2016

First patient recruited to NABNEC

NABNEC, a randomised Phase II clinical trial funded by the NHMRC and supported by Specialised Therapeutics Australia (STA), is now open to patient recruitment. This clinical trial is a study of the combination of nab-Paclitaxel with carboplatin compared with carboplatin in combination with etoposide as treatment for gastrointestinal Neuroendocrine Carcinomas (NECs). … Read More

December 6, 2016

AGITG Preceptorship In Upper GI Cancer

Preceptorship in Upper GI Cancer – now open for applications Dates: Friday 5th & 6th May 2017 Venue: QT Hotel Surfers Paradise QLD Attention: Senior Trainees and Junior Consultants Convenor: A/Prof Eva Segelov Co-Convenor: Dr Lorraine Chantrill Participants from around Australia will be sponsored to attend. This two day intensive … Read More

November 16, 2016

INTEGRATE II recruits first patient

INTEGRATE II, an AGITG led Phase III clinical trial in gastro-oesophageal cancer has opened to recruitment.  Support for the final INTEGRATE II trial design was received from Bayer in November 2015.  INTEGRATE II is a Randomised Phase III Double-Blind Placebo-Controlled Study of regorafenib in Refractory Advanced Gastro-Oesophageal Cancer (AGOC) which … Read More

November 14, 2016

Expert Meeting on Pancreatic Cancer

“Controversies in the management of patients with pancreatic cancer” On Sunday, 18 December a group of AGITG experts will be meeting in Singapore to discuss the controversies in the management of patients with pancreatic cancer. The meeting will be chaired by A/Professor Eva Segelov and attendees include: International Faculty: Prof … Read More

November 14, 2016

Consumer Advisory Panel: Call for EOI

The Australasian Gastro‐Intestinal Trials Group (AGITG) is seeking expressions of interest from people affected by gastro‐intestinal cancer (survivors/patients/carers/family) to join a Consumer Advisory Panel. Background Gastro‐Intestinal cancers are those of the digestive system and include the oesophagus, stomach, liver, gall bladder, pancreas and bowel. The AGITG Consumer Advisory Panel was … Read More

October 26, 2016